Abstract：
BACKGROUND: Adverse drug events (ADEs) are not only a safety and quality of care issue for patients, but also an economic issue with significant costs. Because they often occur during hospital stays, it is necessary to accurately quantify the costs of ADEs. This review aimed to investigate the methods to calculate these costs, and to characterize their nature.
METHODS: A systematic literature review was conducted to identify methods used to assess the cost of ADEs on Medline, Web of Science and Google Scholar. Original articles published from 2017 to 2022 in English and French were included. Economic evaluations were included if they concerned inpatients.
RESULTS: From 127 studies screened, 20 studies were analyzed. There was a high heterogeneity in nature of costs, methods used, values obtained, and time horizon chosen. A small number of studies considered non-medical (10%), indirect (20%) and opportunity costs (5%). Ten different methods for assessing the cost of ADEs have been reported and nine studies did not explain how they obtained their values.
CONCLUSIONS: There is no consensus in the literature on how to assess the costs of ADEs, due to the heterogeneity of contexts and the choice of different economic perspectives. Our study adds a well-deserved overview of the existing literature that can be a solid lead for future studies and method implementation.
BACKGROUND: PROSPERO registration CRD42023413071.
METHODS: A systematic literature review was conducted to identify methods used to assess the cost of ADEs on Medline, Web of Science and Google Scholar. Original articles published from 2017 to 2022 in English and French were included. Economic evaluations were included if they concerned inpatients.
RESULTS: From 127 studies screened, 20 studies were analyzed. There was a high heterogeneity in nature of costs, methods used, values obtained, and time horizon chosen. A small number of studies considered non-medical (10%), indirect (20%) and opportunity costs (5%). Ten different methods for assessing the cost of ADEs have been reported and nine studies did not explain how they obtained their values.
CONCLUSIONS: There is no consensus in the literature on how to assess the costs of ADEs, due to the heterogeneity of contexts and the choice of different economic perspectives. Our study adds a well-deserved overview of the existing literature that can be a solid lead for future studies and method implementation.
BACKGROUND: PROSPERO registration CRD42023413071.
摘要：
背景：不良药物事件（ADE）不仅是患者的安全和护理质量问题，但也是一个成本高昂的经济问题。因为它们经常发生在住院期间，有必要准确量化ADE的成本。这篇综述旨在研究计算这些成本的方法，并描述它们的性质。
方法：进行了系统的文献综述，以确定用于评估Medline上ADE成本的方法，WebofScience和谷歌学者。包括2017年至2022年以英语和法语发表的原始文章。如果涉及住院患者，则包括经济评估。
结果：从筛选的127项研究中，分析了20项研究。成本本质上有很高的异质性，使用的方法，获得的值，和选择的时间范围。少数研究认为非医学（10％），间接成本(20%)和机会成本(5%)。已经报道了十种评估ADE成本的不同方法，九项研究没有解释它们是如何获得它们的价值的。
结论：关于如何评估ADE的成本，文献中没有共识，由于环境的异质性和不同经济视角的选择。我们的研究增加了现有文献的当之无愧的概述，可以为未来的研究和方法实施提供坚实的线索。
背景：PROSPERO注册CRD42023413071。
方法：进行了系统的文献综述，以确定用于评估Medline上ADE成本的方法，WebofScience和谷歌学者。包括2017年至2022年以英语和法语发表的原始文章。如果涉及住院患者，则包括经济评估。
结果：从筛选的127项研究中，分析了20项研究。成本本质上有很高的异质性，使用的方法，获得的值，和选择的时间范围。少数研究认为非医学（10％），间接成本(20%)和机会成本(5%)。已经报道了十种评估ADE成本的不同方法，九项研究没有解释它们是如何获得它们的价值的。
结论：关于如何评估ADE的成本，文献中没有共识，由于环境的异质性和不同经济视角的选择。我们的研究增加了现有文献的当之无愧的概述，可以为未来的研究和方法实施提供坚实的线索。
背景：PROSPERO注册CRD42023413071。
